il21 il23 ccr5与急性移植物抗宿主病的相关研究-study on the relationship between il21 il23 cc r5 and acute graft-versus-host disease.docx

万方数据 万方数据 目 录 中文摘要···········································································································1 英文摘要···········································································································4 英文缩写···········································································································7 研究论文 L21、IL23、CCR5 与急性移植物抗宿主病的相关研究 前言··········································································································9 实验材料与方法···············································································10 结果··········································································································13 附图··········································································································16 附表··········································································································24 讨论··········································································································28 结论··········································································································32 参考文献·······························································································33 综述 急性移植物抗宿主病的生物学指标研究进展 致 谢····················································································································49 个人简历·········································································································50 中 中 文 摘 要 PAGE 10万方数据 PAGE 10 万方数据 IL-21、IL-23、CCR5 与急性移植物抗宿主病的相关研究 摘 要 目的：监测异基因造血干细胞移植 (allo-HSCT)患者，移植不同时间 点的血清 IL-21、IL-23、CCR5 变化，讨论血清中各指标与急性移植物抗 宿主病(aGVHD)发生发展的关系。 方法： 1 研究时间：2014 年 11 月至 2015 年 11 月。 2 研究地点：河北医科大学第二医院血液三区移植层流病房。 3 研究对象：17 例异基因造血干细胞移植患者。 4 病例组临床特点：1）年龄：9-52 岁（中位年龄 33 岁）：男性 10 例，女性 7 例。2）疾病类型：急性髓系白血病（AML）5 例，均为第 1 次完全缓解（CR1），3 例为高危组，1 例为中危组，1 例为标危组。急 性淋巴细胞白血病（ALL）3 例，其中 CR1 2 例，CR2 1 例。急性混合细 胞白血病 1 例，为 CR2。骨髓增生异常综合征（MDS）共 3 例，均为难 治性血细胞减少伴原始细胞增多亚型（MDS-RAEB），并且国际预后积 分系统